Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Guillaumet Adkins, Amy ^a   Richter, Julia ^b   Odero, Maria D ^c   Sandoval, Juan ^a   Agirre, Xabi ^c   Catala, Albert ^d   Esteller, Manel ^a,e,f   Prósper, Felipe ^c   Calasanz, María José ^c   Buño, Ismael ^g   Kwon, Mi ^g   Court, Franck ^a   Siebert, Reiner ^b   Monk, David ^a  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF NAVARRA   (Spain)

^d HOSPITAL SANT JOAN DE DÉU   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Epigenetics; Imprinting; Leukemia; Methylation; WT1

Indexed keywords

DNA; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AWT1 GENE; CANCER CELL CULTURE; CHROMATIN STRUCTURE; COHORT ANALYSIS; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE; GENE OVEREXPRESSION; GENETIC MARKER; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; HISTONE MODIFICATION; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PREDICTIVE VALUE; PROMOTER REGION; SENSITIVITY AND SPECIFICITY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; CHILD; CHILD, PRESCHOOL; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; U937 CELLS; WT1 PROTEINS; YOUNG ADULT;

EID: 84893386005     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-4     Document Type: Article

References (33)

1. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Baird PN, Simmons PJ, Exp Hematol 1997 25 312 320 9131006 (Pubitemid 27236656)
2. The many facets of the Wilms' tumour gene, WT1. Hohenstein P, Hastie ND, Hum Mol Genet 2006 15 Spec 196 R201
3. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumour. Dallosso AR, Hancock AL, Brown KW, Williams AC, Jackson S, Malik K, Hum Mol Genet 2004 13 405 415 14681303 (Pubitemid 38239792)
4. Paternal expression of WT1 in human fibroblasts and lymphocytes. Mitsuya K, Sui H, Meguro M, Kugoh H, Jinno Y, Niikawa N, Oshimura M, Hum Mol Genet 1997 6 2243 2246 10.1093/hmg/6.13.2243 9361029 (Pubitemid 27501075)
5. Alternately spliced WT1 antisense transcripts interact with WT1 sense RNA and show epigenetic and splicing defects in cancer. Dallosso AR, Hancock AL, Malik S, Salpekar A, King-Underwood L, Pritchard-Jones K, Peters J, Moorwood K, Ward A, Malik KT, Brown KW, RNA 2007 13 2287 2299 10.1261/rna.562907 17940140 (Pubitemid 350127568)
6. Identification of differential methylation of the WT1 antisense regulatory region and relaxation of imprinting in Wilms' tumor. Malik K, Salpekar A, Hancock A, Moorwood K, Jackson S, Charles A, Brown KW, Cancer Res 2000 60 2356 2360 10811108 (Pubitemid 30262421)
7. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML. Nomdedéu JF, Hoyos M, Carricondo M, Bussaglia E, Estivill C, Esteve J, Tormo M, Duarte R, Salamero O, de Llano MP, García A, Bargay J, Heras I, Martí-Tutusaus JM, Llorente A, Ribera JM, Gallardo D, Aventin A, Brunet S, Sierra J, Leukemia 2013 27 2157 2164 10.1038/leu.2013.111 23584566
8. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia. Andersson C, Li X, Lorenz F, Golovleva I, Wahlin A, Li A, Diagn Mol Pathol 2012 21 225 233 10.1097/PDM.0b013e318257ddb9 23111196
9. Bi-phenotypic t(9;22)-positive leukemia cell lines from a patient with acute leukemia: NALM-20, established at the onset; and NALM-21, NALM-22 and NALM-23, established after relapse. Matsuo Y, Ariyasu T, Ohmoto E, Kimura I, Minowada J, Hum Cell 1997 4 335 358
10. Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Wu H, D'Alessio AC, Ito S, Wang Z, Cui K, Zhao K, Sun YE, Zhang Y, Genes Dev 2011 25 679 684 10.1101/gad.2036011 21460036
11. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, Berman DM, Jenuwein T, Pruitt K, Sharkis SJ, Watkins DN, Herman JG, Baylin SB, Nat Genet 2007 39 237 242 10.1038/ng1972 17211412 (Pubitemid 46184356)
12. Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. McGarvey KM, Van Neste L, Cope L, Ohm JE, Herman JG, Van Criekinge W, Schuebel KE, Baylin SB, Cancer Res 2008 68 5753 5759 10.1158/0008-5472.CAN-08-0700 18632628
13. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D, Blood 1997 90 1217 1225 9242555 (Pubitemid 27314159)
14. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism. Kwon M, Martínez-Laperche C, Infante M, Carretero F, Balsalobre P, Serrano D, Gayoso J, Perez-Corral A, Anguita J, Diez-Martin JL, Buno L, Biol Blood Marrow Transplant 2012 18 1235 1242 10.1016/j.bbmt.2012.01. 012 22281301
15. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. Alvarez S, Suela J, Valencia A, Fernández A, Wunderlich M, Agirre X, Prosper F, Martin-Subero JI, Maiques A, Acquardo F, Rodriguez Perales S, Calasanz MJ, Roman-Gómez J, Siebert R, Mulloy JC, Cervera J, Sanz MA, Esteller M, Cigudosa JC, PLoS One 2010 5 12197 10.1371/journal.pone.0012197 20808941
16. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthekumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A, Cancer Cell 2010 18 553 567 10.1016/j.ccr.2010.11.015 21130701
17. Expression of Wilm's tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants. Siehl JM, Reinwald M, Heufelder K, Menssen HD, Keliholz U, Thiel E, Ann Hematol 2004 83 745 750 10.1007/s00277-004-0941-0 15340762 (Pubitemid 39485544)
18. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, Miyake S, Tamaki H, Oji Y, Yamagami T, Tatekawa T, Soma T, Kishimoto T, Sugiyama H, Blood 1997 89 1405 1412 9028964 (Pubitemid 27080005)
19. Mutation in TET2 in myeloid cancers. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard OA, N Engl J Med 2009 360 2289 2301 10.1056/NEJMoa0810069 19474426
20. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, Weitzman SA, Korz D, Sukumar S, Cancer Res 2001 61 921 925 11221883 (Pubitemid 32174404)
21. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C, Nat Genet 2000 24 132 138 10.1038/72785 10655057 (Pubitemid 30094712)
22. GATA-1 and GATA-2 binding to 3′ enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines. Furuhata A, Murakami M, Ito H, Gao S, Yoshida K, Sobue S, Kikuchi R, Iwasaki T, Takagi A, Kojima T, Suzuki M, Abe A, Naoe T, Murate T, Leukemia 2009 23 1270 1277 10.1038/leu.2009.13 19212333
23. Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities. Vicente C, Vazquez I, Conchillo A, García-Sánchez MA, Marcotegui N, Fuster O, Gonzalez M, Calasanz MJ, Lahortiga I, Odero MD, Leukemia 2012 26 550 554 10.1038/leu.2011.235 21904383
24. Unique chromatin signature uncovers early developmental enhancers in humans. Rada-Iglesias A, Bajpai R, Swigut T, Brugmann SA, Flynn RA, Wysocka JA, Nature 2011 470 279 283 10.1038/nature09692 21160473
25. Genomic and epigenomic landscape of adult de novo acute myeloid leukemia. The Cancer Genome Atlas Research Network, N Engl J Med 2013 368 98
26. Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia. Carapeti M, Goldman JM, Cross NC, Eur J Haematol 1997 58 346 349 9222290 (Pubitemid 27286667)
27. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. King-Underwood L, Pritchard-Jones K, Blood 1998 91 2961 2968 9531607 (Pubitemid 28227547)
28. Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations. Schumacher V, Schärer K, Wühl E, Altrogge H, Bonzel KE, Guschmann M, Neuhaus TJ, Pollatro RM, Kuwertz-Broking E, Bulla M, Tondera AM, Mundel P, Helmchen U, Waldherr R, Weirich A, Royer-Pokora B, Kidney Int 1998 53 1594 1600 10.1046/j.1523-1755.1998.00948.x 9607189 (Pubitemid 28243741)
29. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study. Little SE, Hanks SP, King-Underwood L, Jones C, Rapley EA, Rahman N, Pritchard-Jones K, J Clin Oncol 2004 22 4140 4146 10.1200/JCO.2004.02.136 15483024 (Pubitemid 41185184)
30. WT1 mutations in T-ALL. Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S, Allen CG, Gale RE, Linch DC, Palomero T, Real P, Murty V, Yao X, Richards SM, Goldstone A, Rowe J, Basso G, Wiernik PH, Paietta E, Pieters R, Horstmann M, Meijerink JP, Ferrando AA, Blood 2009 114 1038 1045 10.1182/blood-2008-12-192039 19494353
31. MGMT gene silencing and benefit from temozolomide in glioblastoma. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R, N Engl J Med 2005 352 997 1003 10.1056/NEJMoa043331 15758010 (Pubitemid 40349502)
32. DNA methylation of GSTP1 as biomarker in diagnosis of prostate cancer. Hopkins TG, Burns PA, Routledge MN, Urology 2007 69 11 16 10.1016/j.urology. 2006.10.008 17270599 (Pubitemid 46201664)
33. Long noncoding RNAs usher in a new era in the biology of enhancers. Ørom UA, Shiekhattar R, Cell 2013 154 1190 1193 10.1016/j.cell.2013.08. 028 24034243